<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTAINED IN THE COMPANY'S QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <MULTIPLIER> 1,000,000 <PERIOD-TYPE> 6-MOS <FISCAL-YEAR-END> DEC-31-2000 <PERIOD-START> JAN-01-2000 <PERIOD-END> JUN-30-2000 <CASH> 136 <SECURITIES> 1,485 <RECEIVABLES> 333 <ALLOWANCES> 21 <INVENTORY> 273 <CURRENT-ASSETS> 2,383 <PP&E> 2,494 <DEPRECIATION> 855 <TOTAL-ASSETS> 4,543 <CURRENT-LIABILITIES> 836 <BONDS> 223 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 0 <OTHER-SE> 3,484 <TOTAL-LIABILITY-AND-EQUITY> 4,543 <SALES> 1,504 <TOTAL-REVENUES> 1,729 <CGS> 187 <TOTAL-COSTS> 187 <OTHER-EXPENSES> 393<F1> <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 8 <INCOME-PRETAX> 824 <INCOME-TAX> 256 <INCOME-CONTINUING> 569 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 569 <EPS-BASIC> 0.55 <EPS-DILUTED> 0.52 <FN> <F1>Item consists of research and development expenses. </FN>